Dmitriy Zamarin

Jan 8, 2025 | nature.com | Jyoti S. Mayadev |Dmitriy Zamarin |Heather A. Lankes |Barbara L. Banbury |Cara Mathews |David M. O’Malley | +1 more

AbstractCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.

Apr 2, 2024 | onclive.com | Dmitriy Zamarin

Dmitriy Zamarin, MD, PhD, section head, Gynecologic Medical Oncology, member, the Icahn Genomics Institute, member, the Precision Immunology Institute, the Tisch Cancer Institute at Icahn School of Medicine, Mount Sinai, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.